Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Avidity Biosciences, Inc. (RNA)
|
Add to portfolio |
|
|
|
| Price: |
$22.72
| | Metrics |
| OS: |
74.1
|
M
| |
-35
|
% ROE
|
| Market cap: |
$1.68
|
B
| |
-50
|
% ROIC
|
|
Net cash:
|
$154
|
M
| |
$2.08
|
per share
|
|
EV:
|
$1.53
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($207)
|
M
| |
|
|
|
EBIT
|
($208)
|
M
| |
|
|
| EPS |
($3.19)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 9.2 | 9.3 | 6.8 | 2.3 | 0.4 |
| Revenue growth | -1.1% | 37.4% | 192.7% | 511.9% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 10.9 |
| Gross profit | 9.2 | 9.3 | 6.8 | 2.3 | -10.5 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | -2769.9% |
| Research and development | 150.4 | 101.2 | 37.6 | 14.5 | |
| General and administrative | 37.7 | 26.2 | 13.5 | 5.1 | 2.4 |
| EBIT | -178.9 | -118.1 | -44.3 | -17.3 | -10.5 |
| EBIT margin | -1939.6% | -1265.8% | -652.4% | -747.4% | -2769.9% |
| Pre-tax income | -174.0 | -118.0 | -44.4 | -24.7 | -11.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -174.0 | -118.0 | -44.4 | -24.7 | -11.2 |
| Net margin | -1886.3% | -1265.4% | -653.5% | -1066.6% | -2959.4% |
| |
| Diluted EPS | ($3.34) | ($2.85) | ($2.05) | ($9.12) | |
| Shares outstanding (diluted) | 52.2 | 41.4 | 21.7 | 2.7 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|